Developer docs
API playgroundTry for free, no card

Search company profiles

Aalto Bio Reagents

Full company profile

uuid000ukf9

Namestring
Aalto Bio Reagents
Company typeenum
Private
Founded yearint
1978
Descriptiontext

Aalto Bio Reagents is a Dublin, Ireland-based private for-profit company founded in 1978 that supplies raw materials to the medical industry. The firm operates with a headcount of 11-50 employees and maintains a branded web presence at aaltobioreagents.com. Its functional focus is the provision of biological and diagnostic reagents — the raw inputs (antigens, proteins, antibodies, and related biochemicals) used by diagnostic kit manufacturers, clinical laboratories, and medical research organizations to produce assays and tests.

The company's product and technology footprint is not detailed in the available source material: no specific SKU catalog, platform architecture, proprietary feature set, or manufacturing process has been disclosed in the inputs provided. The firm is categorized as a for-profit private company headquartered in Dublin, Ireland, with an employee count in the 11-50 range — consistent with a niche specialist supplier rather than a scaled industrial producer. The website and a single observed product page on the parent Biosynth group's diagnostic-reagents taxonomy indicate that Aalto's offerings are now positioned within the broader biologics and diagnostic reagent catalog of Biosynth, suggesting Aalto operates as a sub-brand or product line of a larger group rather than as a fully independent distribution entity.

No revenue model, pricing structure, customer segmentation, distribution channel mix, leadership team, or financial history is available in the source data. As a result, the business model's specifics — how Aalto prices its reagents, whether it sells direct or via distributors, what its customer mix looks like, or how it monetizes its product line — cannot be substantiated beyond the high-level description as a medical-industry raw materials supplier. Any investment assessment of Aalto's commercial mechanics would require additional primary disclosure.

Short descriptiontext

Aalto Bio Reagents is a Dublin, Ireland-based private company founded in 1978 that supplies biological and diagnostic raw materials — antigens, proteins, and related biochemicals — to medical industry customers including diagnostic manufacturers and research laboratories. The firm operates with 11-50 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
diagnostic reagents, biological raw materials, antigens antibodies, in-vitro diagnostics supplies, medical industry reagents
Industry2 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Diagnostic Reagents
Social media profiles1 record
Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aalto Bio Reagents provides raw materials — including diagnostic antigens, antibodies, and related biological reagents — to the medical and in-vitro diagnostics industry. The company manufactures and supplies these biological inputs to diagnostics manufacturers and research laboratories.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information available for Aalto Bio Reagents in the provided sources.

Product and service1 record
1Diagnostic Reagents
CategoryDiagnostic Reagents / Biological Raw Materials
Description

Biological raw materials — antigens, antibodies, and diagnostic reagents — supplied to in-vitro diagnostics manufacturers and biomedical research laboratories for use in assay development and diagnostic kit production.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest global life sciences tools and reagents provider with extensive IVD reagent, antibody, and biochemical raw materials offerings; serves the same diagnostic kit manufacturer customer base as Aalto but with full-line procurement convenience.

TypeDirect peer
Description

UK-based life sciences measurement and reagents company with a strong IVD raw materials and reference standards portfolio; similar specialty positioning and European footprint as Aalto.

TypeEmerging player
Description

Provider of critical raw materials and surface chemistries for IVD and medical device manufacturers; overlapping customer base and raw material positioning with Aalto, though broader in end-use applications.

TypeBroad incumbent
Description

Established clinical diagnostics and life science research products company supplying reagents, controls, and immunoassay materials to IVD manufacturers; directly comparable in customer base and product category to Aalto Bio Reagents.

TypeDirect peer
Description

Global life sciences reagents, peptides, and carbohydrates supplier; Aalto Bio Reagents' diagnostic reagents offering is listed within Biosynth's catalogue, indicating either ownership or close distribution partnership and direct overlap in diagnostic raw materials supply.

TypeBroad incumbent
Description

Diversified life sciences supplier offering IVD-grade reagents, antibodies, and assay components alongside instruments and full workflows; competes with Aalto across diagnostic raw materials but operates at vastly greater scale and breadth.

TypeDirect peer
Description

Specialized diagnostics company offering IVD reagents, controls, and raw materials; similar niche focus on serving diagnostic kit manufacturers with reagent inputs.

TypeRegional player
Description

Spain-based manufacturer of diagnostic reagents and raw materials for infectious disease IVD kits; comparable in scale and product focus, serving a primarily European customer base similar to Aalto's Dublin-headquartered market.

9SeraCare (Revvity)
TypeDirect peer
Description

Provider of diagnostic reference materials, controls, and immunoassay reagents to IVD manufacturers; comparable in scale and specialization with Aalto's diagnostic raw materials focus.

TypeBroad incumbent
Description

Major supplier of bioprocessing and diagnostic consumables, raw materials, and reagents; competes with Aalto for IVD and biopharma manufacturer raw material budgets through a much larger portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aalto Bio Reagents

Diagnostic Reagentsaaltobioreagents.com

Aalto Bio Reagents is a Dublin, Ireland-based private company founded in 1978 that supplies biological and diagnostic raw materials — antigens, proteins, and related biochemicals — to medical industry customers including diagnostic manufacturers and research laboratories. The firm operates with 11-50 employees.

What Aalto Bio Reagents does

Aalto Bio Reagents is a Dublin, Ireland-based private for-profit company founded in 1978 that supplies raw materials to the medical industry. The firm operates with a headcount of 11-50 employees and maintains a branded web presence at aaltobioreagents.com. Its functional focus is the provision of biological and diagnostic reagents — the raw inputs (antigens, proteins, antibodies, and related biochemicals) used by diagnostic kit manufacturers, clinical laboratories, and medical research organizations to produce assays and tests.

The company's product and technology footprint is not detailed in the available source material: no specific SKU catalog, platform architecture, proprietary feature set, or manufacturing process has been disclosed in the inputs provided. The firm is categorized as a for-profit private company headquartered in Dublin, Ireland, with an employee count in the 11-50 range — consistent with a niche specialist supplier rather than a scaled industrial producer. The website and a single observed product page on the parent Biosynth group's diagnostic-reagents taxonomy indicate that Aalto's offerings are now positioned within the broader biologics and diagnostic reagent catalog of Biosynth, suggesting Aalto operates as a sub-brand or product line of a larger group rather than as a fully independent distribution entity.

No revenue model, pricing structure, customer segmentation, distribution channel mix, leadership team, or financial history is available in the source data. As a result, the business model's specifics — how Aalto prices its reagents, whether it sells direct or via distributors, what its customer mix looks like, or how it monetizes its product line — cannot be substantiated beyond the high-level description as a medical-industry raw materials supplier. Any investment assessment of Aalto's commercial mechanics would require additional primary disclosure.

Aalto Bio Reagents firmographics

Firmographics
Name
Aalto Bio Reagents
Website
https://aaltobioreagents.com
Company type
Private
Founded year
1978
Operating status
Operating
Headcount range
11–50 employees
Short description
Aalto Bio Reagents is a Dublin, Ireland-based private company founded in 1978 that supplies biological and diagnostic raw materials — antigens, proteins, and related biochemicals — to medical industry customers including diagnostic manufacturers and research laboratories. The firm operates with 11-50 employees.
Ownership category
akta.pro rank

Aalto Bio Reagents industry classification

Industry
Product category
Diagnostic Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Diagnostic reagents
  • Biological raw materials
  • Antigens antibodies
  • In-vitro diagnostics supplies
  • Medical industry reagents

Where Aalto Bio Reagents is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Markets served

Aalto Bio Reagents business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Aalto Bio Reagents product offering

Product offering

Core offering

Aalto Bio Reagents provides raw materials — including diagnostic antigens, antibodies, and related biological reagents — to the medical and in-vitro diagnostics industry. The company manufactures and supplies these biological inputs to diagnostics manufacturers and research laboratories.

Product overview

No product information available for Aalto Bio Reagents in the provided sources.

Differentiator

Problem solved

Functional benefit

Products and services

  • Diagnostic Reagents Biological raw materials — antigens, antibodies, and diagnostic reagents — supplied to in-vitro diagnostics manufacturers and biomedical research laboratories for use in assay development and diagnostic kit production.

Companies that use Aalto Bio Reagents

Customer profile

Ideal customer profiles1 record

Aalto Bio Reagents technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Aalto Bio Reagents partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights2 records

Aalto Bio Reagents competitors and assessment

Company assessment

Broad incumbents

  • Thermo Fisher Scientific: Largest global life sciences tools and reagents provider with extensive IVD reagent, antibody, and biochemical raw materials offerings; serves the same diagnostic kit manufacturer customer base as Aalto but with full-line procurement convenience.
  • Bio-Rad Laboratories: Established clinical diagnostics and life science research products company supplying reagents, controls, and immunoassay materials to IVD manufacturers; directly comparable in customer base and product category to Aalto Bio Reagents.
  • Merck KGaA (Sigma-Aldrich): Diversified life sciences supplier offering IVD-grade reagents, antibodies, and assay components alongside instruments and full workflows; competes with Aalto across diagnostic raw materials but operates at vastly greater scale and breadth.
  • Cytiva (Danaher): Major supplier of bioprocessing and diagnostic consumables, raw materials, and reagents; competes with Aalto for IVD and biopharma manufacturer raw material budgets through a much larger portfolio.

Direct peers

  • LGC Group: UK-based life sciences measurement and reagents company with a strong IVD raw materials and reference standards portfolio; similar specialty positioning and European footprint as Aalto.
  • Biosynth: Global life sciences reagents, peptides, and carbohydrates supplier; Aalto Bio Reagents' diagnostic reagents offering is listed within Biosynth's catalogue, indicating either ownership or close distribution partnership and direct overlap in diagnostic raw materials supply.
  • EKF Diagnostics: Specialized diagnostics company offering IVD reagents, controls, and raw materials; similar niche focus on serving diagnostic kit manufacturers with reagent inputs.
  • SeraCare (Revvity): Provider of diagnostic reference materials, controls, and immunoassay reagents to IVD manufacturers; comparable in scale and specialization with Aalto's diagnostic raw materials focus.

Emerging players

  • Surmodics: Provider of critical raw materials and surface chemistries for IVD and medical device manufacturers; overlapping customer base and raw material positioning with Aalto, though broader in end-use applications.

Regional players

  • Vircell: Spain-based manufacturer of diagnostic reagents and raw materials for infectious disease IVD kits; comparable in scale and product focus, serving a primarily European customer base similar to Aalto's Dublin-headquartered market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Aalto Bio Reagents social profiles

Digital presence

Aalto Bio Reagents financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aalto Bio Reagents leadership team

Management profile

Number of profiles

Aalto Bio Reagents funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aalto Bio Reagents M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aalto Bio Reagents

What does Aalto Bio Reagents do?

Aalto Bio Reagents provides raw materials — including diagnostic antigens, antibodies, and related biological reagents — to the medical and in-vitro diagnostics industry. The company manufactures and supplies these biological inputs to diagnostics manufacturers and research laboratories.

Is Aalto Bio Reagents a public or private company?

Aalto Bio Reagents is a private company. It is classified as unknown and is currently operating.

When was Aalto Bio Reagents founded?

Aalto Bio Reagents was founded in 1978. It employs 11 to 50 people.

Where is Aalto Bio Reagents based?

Aalto Bio Reagents is headquartered in Dublin, Ireland, in the Europe region.

Who are Aalto Bio Reagents's main competitors?

Broad incumbents on record are Thermo Fisher Scientific, Bio-Rad Laboratories, Merck KGaA (Sigma-Aldrich) and Cytiva (Danaher). Direct peers are LGC Group, Biosynth, EKF Diagnostics and SeraCare (Revvity). Surmodics is listed as an emerging player. Vircell is listed as a regional player.

Does Aalto Bio Reagents have an API?

No public API is recorded for Aalto Bio Reagents.

What industry is Aalto Bio Reagents in?

Aalto Bio Reagents's product category is Diagnostic Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireIVD Raw Materials Focused Insights Report 2024: A $38+ Bn Market by 2029 Featuring Key Players - Merck, Fujirebio, Aalto Bio Reagents, Fapon Biotech, F. Hoffmann-La Roche, and Thermo Fisher ScientificThe global IVD raw materials market is projected to grow from $26.98 billion in 2023 to $38.05 billion by 2029, a CAGR of 5.9%. European region dominates, with key players including Merck, Fujirebio, and Thermo Fisher. Growth is driven by demand for advanced diagnostics and microfluidic technology.BioSpaceBiosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio ReagentsBiosynth Carbosynth acquired Aalto Bio Reagents, a provider of biological materials for IVD and vaccine development. The deal expands Biosynth's offering to IVD customers with proteins, antigens, antibodies, and biospecimens for emerging diseases. The acquisition is part of Biosynth's strategy to become a leading global supplier to biopharma and diagnostics.GlobeNewswireAalto Bio Targets 15 of the World's Most Dangerous VirusesAalto Bio Reagents announced a new strategy to develop diagnostic targets for 15 of the world's most dangerous viruses, including Zika, Dengue, and Ebola. The company, a Dublin-based provider of raw materials for IVD, will add new development materials to its infectious disease portfolio.NewswireAalto Bio Reagents Announces Its New Sars-Cov-1 Spike Protein S1 DomainAalto Bio Reagents announced its new Sars-Cov-1 spike protein S1 domain, part of a suite of coronavirus proteins for diagnostic testing. The company has supported over 120 global diagnostic companies and vaccine developers since January 2020, and will offer free material to the first three scientists for Sars-Cov-1 research.PR NewswireAalto Bio Reagents Launches First nCOV Nucleocapsid Based Monoclonal Antibody for Antigen Testing for COVID 19Aalto Bio Reagents announced the launch of its first mouse monoclonal antibody (code CA 1360) against SARS-CoV-2 nucleocapsid protein for use in COVID-19 antigen detection assays including ELISA, Western blot, and lateral flow tests. The company positioned this product as a higher-quality raw material for rapid antigen tests, citing accuracy concerns with existing options particularly for asymptomatic individuals. The CEO stated the company aims to address these accuracy gaps in high-volume screening scenarios such as airports.PR NewswireAalto Bio Reagents announces it is supplying reagents for the manufacturing of tens of millions of COVID-19 antibody tests per monthAalto Bio Reagents announced it is supplying critical raw materials, including Sars-CoV-2 antigens, lysis buffers, and viral transport media, for the manufacturing of tens of millions of COVID-19 antibody tests per month. The company's products are being used in diagnostic assays deployed on the COVID-19 screening front line in Europe and the U.S., supporting over 50 global diagnostic companies and vaccine developers. CEO Philip Noone stated the company will continue to innovate and support diagnostic manufacturing partners to meet COVID-19 testing requirements.PR NewswireAalto Bio Reagents Launches New Recombinant Eukaryotic SARS-CoV-2, S1-S2 Spike Proteins for Improved Diagnostic Testing of COVID-19Aalto Bio Reagents announced the launch of its new range of recombinant SARS-CoV-2 S1-S2 spike proteins for diagnostic test manufacturers, vaccine developers, and researchers globally. The S1-S2 chimeric glycoprotein has demonstrated excellent reactivity in ELISA tests for detection of IgA, IgG, and IgM antibodies against SARS-CoV-2. The company stated these proteins were developed to meet urgent diagnostic needs, particularly for detecting mild and asymptomatic COVID-19 cases that PCR testing may miss.PR NewswireAalto Bio Reagents Launches rna Lysis Buffer Reagent for Use in Hospitals and Laboratories for COVID-19 TestingAalto Bio Reagents developed and delivered an RNA Lysis buffer reagent for COVID-19 sample pre-treatment in response to a request from the Health Service Executive (HSE). The company completed this development in four weeks, addressing a critical supply shortage of diagnostic reagents in Europe. This effort aims to alleviate bottlenecks in the COVID-19 testing supply chain.PR NewswireCombating the Scourge of Infectious Disease a Focus at AACC 2017 in San DiegoCompanies including Ortho Clinical Diagnostics, Aalto Bio Reagents, and Seegene Inc. showcased new infectious disease detection products and reagents at the AACC 2017 conference in San Diego. These announcements highlight industry advancements such as faster HIV assays, recombinant Yellow Fever Virus proteins, and rapid multiplex PCR systems for conditions like sepsis and tuberculosis. The event underscores the competitive nature of the in vitro diagnostics market as firms strive to improve early detection and treatment outcomes.PR NewswireYFV Protein, Middle East Markets, Gene Editing and "Data Lakes" are among Developments at First Day of AACC 2017 in San DiegoThe American Association for Clinical Chemistry (AACC) 2017 meeting in San Diego featured product launches and strategic announcements from major in vitro diagnostics companies, including Aalto Bio Reagents, Seegene Inc., Beckman Coulter, and Roche. Key developments included the debut of a recombinant Yellow Fever Virus protein by Aalto Bio Reagents and new diagnostic platforms from Seegene and Beckman Coulter aimed at improving testing speed and standardization. Additionally, AACC announced the launch of a new conference in Abu Dhabi to target Middle East market growth, while Roche showcased its 'connected lab' concept.